Venture Victories

Venture Victories is a regularly published roundup from VCU TechTransfer and Ventures that highlights recent successes from startups created from VCU intellectual property.

Air Force awards $1.8M to VCU startup to advance development of drug treating massive blood loss

Researchers at Virginia Commonwealth University could soon launch a clinical trial to test an intravenous solution that its inventor, a School of Medicine physiologist and surgery professor, says might treat massive blood loss in trauma patients.

Perfusion Medical Inc., a VCU startup working to commercialize the drug called PM-208, has received $1.8 million from the U.S. Air Force that moves the company a step closer to starting clinical trials.

“For a person who is bleeding out, PM-208 may take survival time from minutes to a day or more,” said Martin J. Mangino, Ph.D., a professor of surgery and of physiology and biophysics in the School of Medicine.

Story continues here...

 


 

With VCU licenses, Minnesota biotech secures funding as it moves toward commercialization of lung cancer, pneumothorax treatments

Quench Medical, a Minnesota biotechnology company that has licensed aerosol technologies from two VCU researchers continues to secure federal grants as it moves closer to commercialization. The company is developing inhaled aerosol therapies to treat both lung cancer and lung leaks (pneumothorax).

Quench’s IP comes from a 16-year research partnership into aerosol-based therapies with the VCU School of Pharmacy’s Michael Hindle, Ph.D. and the VCU College of Engineering’s P. Worth Longest, Ph.D. VCU TechTransfer and Ventures worked with Hindle and Longest to license some of their IP to Quench in 2022. “This collaboration is a perfect example of the power of bridging academia and industry together with the promise of improving patient outcomes and revolutionizing healthcare delivery,” says Brittaney Ritchie, VCU TechTransfer and Ventures’ medical devices licensing manager.

Story continues here


 

Blood-loss and critical illness drug startup gets $2.9 million on path to human studies

A startup to stop hemorrhagic shock and treat cardiac and other critical illnesses has a new infusion of capital on its road to the first tests in humans.
 
Perfusion Medical this fall was awarded a $2.9 million grant from the Defense Health Agency. The Small Business Innovation Research (SBIR) funding will enable the company to complete pre-clinical studies and submit an Investigational New Drug (IND) application to the FDA for its drug candidate, called PM-208 (developed under the name PEG-20k). The solution was invented by a team led by Martin J. Mangino, Ph.D., a professor of surgery, physiology and biophysics in the Department of Surgery at the VCU School of Medicine.

Story continues here


 

Find more about Perfusion Medical, see this January 2023 story in the Richmond Times-Dispatch


 

VCU muscle-loss startup picks up funding for “scaffolding” tech

A VCU biomedical engineer is on a mission to better repair muscle injuries, and today has a bit
more funding to help him achieve it.

Michael McClure, Ph.D., an assistant professor in the College of Engineering’s Department of
Biomedical Engineering, was this summer awarded $75,000 by the Virginia Innovation
Partnership Corp. to pursue a new method of repairing muscle loss and tears. His intellectual
property is also the basis of a startup, Sarcogenics.

Continued here...


By the way: McClure’s company, Sarcogenics, is related to the term sarcopenia, the progressive loss of muscle due to age. Age plays a significant role in injury severity and a role in surgical success.In rotator cuff surgeries in particular, almost 50% of surgeries re-tear within a 12-month period. Part of the goal of the research team’s scaffolding material is to improve surgical success in patients with advanced age.


 

Federal grant will help VCU researchers build forensics business to serve national crime labs

A VCU startup that is developing technologies to improve forensic investigations has been awarded a grant from the National Science Foundation.

The $270,578 Phase I Small Business Technology Transfer (STTR) award to Rapid Forensic Cell Typing will help the company develop technology that can analyze “non-genetic attributes” of cells within forensic evidence, explains VCU researcher Christopher Ehrhardt, Ph.D., a co-investigator on the project and professor in the Department of Forensic Science at the VCU College of Humanities and Sciences.

Continued here...

Action Items:

Minnesota biotech using VCU IP secures federal funds

Minnesota-based company Quench Medical, which has licensed aerosol technologies from two VCU researchers, secured $2 million in federal grants for the continued development of an inhaled therapy for lung cancer.

Continued here...

Action Items:

  • Hindle and Longest also were recently awarded $3.2 million from the Bill & Melinda Gates Foundation to further their research. Read more.

 


 

Perfusion Medical accepted into Boston-based tech accelerator program

Perfusion Medical has been accepted at the prestigious MassChallenge U.S. Early Stage Accelerator program. 

Continued here...


 

Air Force issues awards to VCU-backed shock therapeutic startup Perfusion Medical

The U.S. Air Force’s venture capital and innovation arm, AFWERX, has awarded two grants to a Herndon and Richmond, Virginia - based startup using technology developed by VCU researchers.

Story continues here...


 

VCU VR startup focused on mental health intervention gets NIMH award

A VCU startup exploring virtual reality to treat mental health in kids who are at risk of behavioral disorders received $275,000 this spring from the National Institute of Mental Health.

Story continues here...

Action Items: